time corona assess
potenti impact across
unpreced time extrem market volatil uncertainti around
pandem categor sinc march
taken critic look across coverag better assess like impact
much unknown echo numer convers client corpor
alik maintain biopharma highli defens sector like find
treatment potenti vaccin inde gilead regeneron work
potenti treatment long-term thesi remain unchang gilead still need build
pipelin continu bullish regeneron optimist compani
help fight pandem could get initi remdesivir data mid-april
posit could welcom news societi regeneron like data kevzara
trial use help dampen immun respons sever patient may
estim trial therapeut antibodi program like start summer still
public health perspect extrem social distanc best tool help
flatten curv reduc transmiss rate await therapeut
option like endur sever week potenti month
beyond suggest date mid-april administr
yet confirm coverag gener expect guidanc
updat even withdrawn earn call late april/ earli may think
jnj cfo wolk character best wsj regard guidanc one
thing know certain go precis wrong sentiment echo
uncertainti fluid situat still make sens current environ examin
major coverag commerci pre-commerci compani along
follow metric revenue/commerci busi clinic trial suppli chain financ risk
commerci busi resili defin patient popul home
administr vs new launch in-offic administr gener think clinic
trial face delay even oncolog trial patient may difficulti get clinic
get scan less concern suppli chain compani
multipl supplier api china start reopen follow lockdown
coverag strong balanc sheet surviv current uncertainti howev
note may need access capit market given current model
reiter playbook happen next fluiditi
pandem make difficult accur assess thing get back normal within two month
impact like less sustain pandem summer fall
treatment asid think vertex posit strongest
us commerci perspect although eu launch trikafta may slow aimmun
like expos recent launch palforzia regulatori front
gilead/galapago could experi delay fda current paus non-
essenti meet april like extend pandem continu
chang rate rel view note posit headlin could drive
temporari gilead upsid continu maintain regeneron top pick
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
tabl content
one defens sector pandem
compani specif impact coverag
one defens sector
pandem
posit favor rel sector short-term disrupt
like despit recent weak volatil market believ biotech better
posit sector current environ major biotech pharma
player may see resili due treatment develop effort
seen year regeneron gilead ytd respect
seen share increas news flow relat develop novel treatment see
tabl perform coverag also believ less elast demand
therapeut product may mitig commerci disrupt furthermor busi
fundament resist effect potenti econom slowdown
sector believ demand novel product treat unmet need persist longer-
term outlook rel unchang addit believ feder govern shift
sentiment toward favor view biotech/pharma compani could provid
broader support compani work toward potenti treatment
vertex cf franchis rare diseas disease-modifi oral product like resili
neurocrin specialti distribut direct-to-pati mail mitig risk disrupt
current valuat offer attract entri point long-term stori base busi
resili bolster pipelin growth biosimilar remain unchang
mirati overal thesi still intact despit risk trial disrupt
satsuma fundament unchang potenti trial delay thesis-alt
potenti impact recent near-term drug launch
regeneron dupix asthma still earli inning expect reduc patient start
gilead/galapago anticip launch filgotinib risk pandem persist
aimmun palforzia launch risk disrupt treatment burden child caregiv may
caus patient defer treatment initi pandem resolv
potenti impact clinic timelin
gilead/galapago filgotinib indic uc paus enrol
neurocrin valbenazin huntington diseas studi risk enrol delay
regeneron oncolog product face risk enrol delay includ libtayo novel
prefer name exclud potenti treatment
vertex expect limit impact commerci cf busi due sever
diseas conveni oral administr vertex product
mirati fundament outlook remain unchang potenti clinic trial
disrupt unlik impact valuat consider mitig high
figur biotech perform coveragemarch present ytd
meanwhil believ short-term disrupt like compani alreadi
announc delay clinic trial galapago lilli recent state recruit
clinic trial paus result highlight key risk
compani compani specif discuss later report
revenu risk would expect lower revenu commerci compani across
coverag howev product target indic lower acut need afflict
elderli and/or reli steadi flow new patient start like higher risk
addit multipl compani pull sale forc field could
meaning impact launch new drug degre impact time remain
challeng quantifi given dynam environ even compani
go forward would expect compani revis guidanc
highlight actual revenu could vari consider current situat resolv
near-term would expect revenu case recov somewhat patient
return clinic viru concern disappear
clinic trial disrupt includ regulatori risk compani
previous state trial disrupt occur believ delay current
on-going trial like expert believ case increas near-term
next week would could see compani paus recruit on-going
plan trial patient self-quarantin trial enrolle also
like miss schedul visit could lead increas discontinu on-going
trial could mean inconsist data report although virtual check-in
compani could mitig issu overal think establish commerci
compani impact less meaning howev smaller compani could see
modest impact especi asset higher competit compani healthi cash
posit need access capit market near-to-mid-term better
insul downsid regulatori perspect believ could
impact/delay pdufa action date potenti regulatori interact relat
ongoing/plan trial dont expect substanti fundament impact
compani cover near-term may add anoth layer uncertainti current
environ potenti push back expect drug launch month
product suppli shortfal cover compani gener report
little-to-no suppli clinic trial disrupt although could chang situat
worsen could relev larger commerci compani coverag
particularli medic requir complex mode administr novel
devic less critic medic believ commerci product conveni
self-administr high rate complianc due necess diseas sever
reason better posit also see greater risk compani reli
mainli revenu singl product manufacturing/ suppli issu remain problem
month could impact abil compani produc adequ drug
clinic studi commerci scale
financi risk estim compani particularli pre-commerci may face
challeng ahead fund oper limit cash balanc hand view
like challeng rais capit current environ futur
economi remain unclear could see pullback capit rais given
figur potenti impact compani coverag univers
companyrevenu commentarytri commentarysuppli chain commentaryfinanci riskaimmuneth compani launch palforzia us like face headwind due disrupt palforzia approv januari rem program went live februari initi administr palforzia initi dose dose interv everi week requir in-offic administr monitor rem certifi facil believ patient may delay clinic interact defer treatment situat return normal compani current enrol us patient trial egg allergi compani disclos delay enrol trial timelin compani suppli chain entir us-bas compani disclos disrupt date aimmun healthi cash posit support launch activ follow receipt financ nestl februari addit borrow bring total cash equival limit expect revenu across much cover compani impact at-home/or administr mani product like mitig sever disrupt believ oncolog ckd franchis resili given necess treatment enbrel weekli at-hom auto-inject also like support patient complianc key pipelin asset on-going clinic trial site us europ asia nsclc mm tezepelumab asthma omecamtiv mecarbil hf delay yet disclos see risk potenti delay due disrupt reach comment compani state date nothad disrupt suppli finish good inventori healthi posit raw materi procur small portion china monitor inventori level take addit measur mitig raw materi suppli interrupt part on-going busi continu effort eseeabl risk limit due cash posit debt/ltm ebitdaw expect limit impact oral inject ms franchis though see risk tysabri sale ocrevu royalti given in-offic infus administr spinraza believ sever sma necessit treatment well twice/year dose interv limit commerci disrupt franchis on-going trial site us europ pd choroideremia xlrp potenti risk delay februari compani disclos multipl employe contract though yet announc delay trial disrupt directli relat trial could see risk regulatori action around aducanumab recent investor confer manag comment versu thecurr crisi suppli chain good eseeabl risk limit due cash posit debt/ltm ebitdagalapagoswhil pre-commerci see risk filgotinib commerci launch signific disrupt pandem extend disclos recruit paus filgotinib trial compani state timelin top-line result phase select program unchang data expect trial oa underway us disclos disrupt date eseeabl risk limit due eur cash posit galeran/a pre-commercialwith regard galera report impact toth busi suppli enrol etc on-going trial current enrol usand canada plan initi om trial europ disclos disrupt date galera like need rais capit end given cash hand run-rat annual expens greater anticip addit fund need complet develop build commerci capabl ahead estim launch gileadw believ gilead hiv franchis posit resili outbreak given avail prescript day suppli well oral administr see risk yescarta sale given infus requir requir day in-facil monitor post-infus also see possibl chanc disrupt filgotinib anticip launch signific disrupt persist disclos recruit paus filgotinib trial compani state timelin top-line result phase select program unchang data expect trial oa underway us reach comment compani disclos foreseen disrupt manufactur suppli raw materi gener avail multipl sourc purchas world-wide normal avail quantiti adequ meet need busi attempt manag risk associ suppli chain inventori manag relationship manag evalu altern sourc feasibl eseeabl risk limit due cash posit debt/ltm charl martineau pm univers toronto
figur potenti impact compani coverag univers
companyrevenu commentarytri commentarysuppli chain commentaryfinanci riskincytew expect jakafi resili pandem broadli expect oral oncolog medic maintain normal rate patient complianc on-going trial site us eu asia ruxolitinib gvhd pemigatinib cca compani on-going trial site us eu itacitinib gvhd topic ruxolitinib vitiligo ad strategi maintain month safeti stock api abl respond chang demand provid on-tim suppli drug product well least month semi-finish good inventori current raw materi use manufactur ruxolitinib phosphat api jakafi suppli chinese-bas compani result intern trade disput china unit state action chines govern would limit prevent chines compani suppli materi would advers affect abil manufactur suppli product meet market need materi advers effect oper result forese need capit given profit commerci busi cash hand debt/ltm ebitdan/a pre-commercialtri site us eu asia underway margetuximab gastric cancer us trial underway enoblituzumab scchn report impact current studi stage follow-up manag howev compani factor slight delay start mahogani modul led zai lab report disrupt date expect need access capit compani cash balanc project suffici fund cash usag miratin/a pre-commercialtri underway nsclc monotherapi combin nsclc follow-up manag mirati state direct impact across supplier compani multi-sourc ds dp across multipl countri current ad supplier addit countri mirati expect rais capit next year compani cash hand complet follow-on equiti offer januari sale sensit season may exacerb disrupt howev ingrezza prescript fill direct-to-pati deliveri mitig seriou impact expect anticip launch opicapon pd pdufa april may face headwindsu trial underway vy-aadc pd compani disclos trial disrupt date report suppli chain disrupt due unrel issu opicapon due bial plant issu immin need cash compani end balanc sheet core busi profit limit need addit capit regeneronw believ dupix at-hom self-administr mitig sever disrupt howev see risk eylea due in-offic administr eylea week dose interv may reduc impact patient may look lengthen dose interv possibl given desir limit clinic interact trial site us eu on-going fasinumab pain trial libtayo nsclc includ site eu asia compani disclos trial disrupt date convers compani manag state regeneron pois handl suppli disrupt note current year drug substanc eylea reserv well ampl materi market pipelin asset includ dupix forese risk limit due cash posit debt/ltm ebitdasatsuman/a migrain studi underway unit state compani disclos trial disrupt date report suppli chain disrupt speak compani compani indic suffici cash compani end cash hand project spend per year vertexw believ vertex cystic fibrosi portfolio rel well-insul sever disrupt vertex therapeut disease-alt oral administ treatment rare diseas expect patient complianc remain normal level studi us eu site includ cf scd us trial underway reach comment compani respond construct suppli chain situat like one mind prepar conting build signific safeti stock suppli chain manag disrupt addit second sourc supplier geograph divers addit confid uninterrupt commerci suppli expect disrupt suppli medicin use clinic trial forese risk limit due cash posit debt/ltm charl martineau pm univers toronto march
compani specif impact coverag
expect launch palforzia sensit disrupt across multipl
front salesforc product may neg impact reduced/alt interact
potenti prescrib palforzia in-offic administr requir up-dos
interv creat treatment burden caregiv children peanut allergi may lead
mani postpon treatment initi pandem resolv peanut allergi patient
school moment like home environ much easier
control practic avoid current environ see physician
parent risk er visit due anaphylaxisand thu would highli unlik start palforzia
revenu risk compani launch palforzia us like face headwind due
disrupt palforzia approv januari rem program went live
februari recent press releas indic patient begun dosingbut
think widespread use unlik least remaind
believ parent may defer treatment children situat return normal
particularli given treatment burden dose phase treatment protocol
trial risk compani current enrol us patient trial egg allergi
compani disclos delay enrol trial timelin howev see potenti
disrupt trial enrol across indic geographi
includ us
suppli chain risk compani suppli chain entir us-bas compani
disclos disrupt date
financi risk aimmun healthi cash posit support launch activ follow
receipt financ nestl februari addit borrow
bring total cash equival
see limit revenu risk given highli diversifi commerci portfolio
clinic trial risk also lower sever key trial alreadi fulli enrol meanwhil could
see suppli chain risk compani state consider inventori
hand still recent convers got sens hesit
fulli rule guidanc revis note otezla recent becam part
portfolio unlik experi sort meaning growth
guidanc revenu non-gaap ep somewhat
conserv view could see situat guidanc maintain contrari
prior view set beat-and-rais year new cfo
revenu risk see limit exposur revenu at-home/or
administr mani product like mitig sever disrupt
discuss compani us sale staff use work virtual less like
see major disrupt current direct us sale staff move entir
virtual work model oncolog ckd franchis believ asset
resili given necess treatment enbrel weekli at-hom auto-inject
also like support patient complianc also state enbrel script refil
trial risk key pipelin asset on-going clinic trial site us europ
asia nsclc mm tezepelumab asthma omecamtiv mecarbil
hf delay yet disclos howev believ risk potenti delay due
disrupt still like convers state fluid situat
make challeng estim potenti impact individu trial look
altern way assess endpoint protocol amend need
compani also highlight potenti fda flexibl given current challeng
scan perform everi week critic assess responsethu data
phase pivot may delay key trial tezepelumab omecamtiv
mecarbilboth full enrol
suppli chain risk believ greater suppli chain risk given larg number
commerci asset could less impact short-term state
residu inventori level common compani henc short-term
suppli like suffici get next sever month view
reach comment compani state date disrupt suppli
finish good inventori healthi posit raw materi procur
small portion china monitor inventori level take
addit measur mitig raw materi suppli interrupt part on-going
financi risk limit financi risk due cash posit abil
rais addit debt need current lever debt/ltm ebitda
potenti valuat impact use price januari prior market shock
current consensu estim ep estim could trade
disrupt lead flat yoy earn growth turn price-to-earnings multipl
compress price end januari figur
scenario forward price-to-earnings multipl
believ commerci portfolio limit exposur
environmentmuch ms portfolio either at-hom oral tecfidera inject
interferon tysabri infus ocrevu mainten therapi also
highlight spinraza consid essential/ non-elect still anecdot
report delay dose due hospit constrains/ concern relat
concern potenti delay aducanumab file compani yet file
fda despit earli timelin maintain aducanumab remain largest
driver share
revenu risk expect limit impact oral inject ms franchis though
see risk tysabri sale ocrevu royalti given in-offic infus administr
spinraza believ sever sma necessit treatment well twice/year
dose interv limit commerci disrupt franchis
trial risk on-going trial site us europ pd
choroideremia xlrp potenti risk delay februari
compani disclos multipl employe contract though yet
announc delay trial disrupt regulatori standpoint believ biggest
risk file bla aducanumab per compani commentari suppos earli
indic delay due
convers compani indic press releas would issu upon
bla file fda like throughout regulatori process beyond file bla
look forward potenti accept fda like advisori committe meet
suggest delay process fda cancel non-essenti
meet april could extend may even june
suppli chain risk similar larg cap compani report disrupt
suppli chain howev develop could see possibl disrupt
better understand full extent crisi
financi risk forese risk limit due cash posit capac rais
addit debt current lever debt/ltm ebitda
potenti valuat impact use price januari prior market shock
current consensu estim ep estim could trade
disrupt lead acceler earn declin turn price-to-earnings multipl
compress price end januari figur
scenario forward price-to-earnings multipl
believ gilead commerci busi remain resili throughout pandem given
necess chronic hiv treatment well patient conveni aspect one-daili
oral administr eas refil prescript beyond hiv anticip commerci
headwind yescarta well anticip launch filgotinib depend scope
durat pandem expect social distanc protocol may lead reduc
clinic interact neg impact patient start treatment non-lif threaten
diseas neg impact descovi prep convers filgotinib initi launch
treatment cautious optimist compani plan
advanc remdesivir treatment initi data expect april posit
anticip share price appreci due posit sentiment in-lin previou
manag commentari expect gilead develop meaning commerci
busi around remdesivir least near-term see much potenti upsid
sentiment-driven rather fundament valuat perspect
six on-going trial remdesivir
gilead studi patient moder diseas
gilead studi patient sever diseas
china studi patient mild/moder diseas
china studi patient sever diseas
revenu risk believ gilead hiv franchis posit resili
outbreak given avail prescript day suppli well conveni
oral self-administr see risk yescarta sale given infus requir
requir day in-facil monitor post-infus also see possibl chanc disrupt
filgotinib anticip launch signific disrupt persist
trial risk gilead/galapago disclos recruit paus filgotinib trial
compani state timelin top-line result phase select program
unchang data expect
recent convers compani indic mani trial paus
enrollmentsom trial exempt name patient outcom could critic
impact name capsid inhibitor program trial involv multi-drug resist hiv
suppli chain risk reach comment compani disclos foreseen
disrupt manufactur suppli api sourc china hiv
hcv portfolio product multipl sourc unlik impact
raw materi gener avail multipl sourc purchas
world-wide normal avail quantiti adequ meet need busi
attempt manag risk associ suppli chain inventori manag
relationship manag evalu altern sourc feasibl
remdesivir gilead note current limit suppli commerci
product typic ramp take year compani note stock pile
product follow recent ebola outbreak gilead also acceler manufactur
timelin increas suppli
financi risk minim impact gilead end cash equival
potenti valuat impact use price januari prior market shock
current consensu estim ep estim gilead could trade
disrupt lead acceler earn declin turn price-to-earnings multipl
compress price end januari figur
scenario forward price-to-earnings multipl
anticip filgotinib commerci launch may face pandemic-rel headwind
social distanc protocol may lead reduc clinic interact neg impact patient
start treatment non-lif threaten diseas pandem persist
revenu risk pre-commerci see risk filgotinib commerci launch signific
disrupt pandem extend given avail treatment altern
limit virtual salesforc interact europ compani note gap
european launch rinvoq filgotinib could shrunk
activ commerci asset much europ moment
trial risk gilead/galapago disclos recruit paus sever
filgotinib trial includ phase phase trial filgotinib crohn divers phase
psoriat arthriti penguin phase uveiti manta/ manta-ray trial
phase ankylos spondyl start later
compani state timelin top-line result phase select program
unchang data expect trial oa underway us
toledo program asset see risk delay timelin trial yet initi
expect pose challeng new trial initi patient enrol note
trial ipf patient total enrol compani
protocol continu trial given sever diseasew could see
interrupt pandem worsen us europ
suppli chain risk disclos disrupt date
financi risk forese need access capit market within next sever year
galapago end eur cash
clinic trial risk compani report trial delay far expect trial enrol
potenti delay particularli longer term note on-going trial current
enrol us canada plan initi om trial europ
situat evolv could see enrol paus north america
enrol europ delay note galera oncolog focu trial may provid
priorit necessari less sever diseas
suppli chain risk clinic trial drug suppli impact current
financ risk galera like need rais capit end given cash
hand run-rat annual expens greater anticip addit fund
need complet develop build commerci capabl
ahead estim launch
believ gener well posit environ revenu
risk gener limit given priorit oncolog drug patient could see
clinic trial risk go forward rel contribut share modest
compar jakafi
commerci risk expect jakafi resili pandem broadli
expect oral oncolog medic maintain normal rate patient complianc
clinic trial risk on-going trial site us eu asia ruxolitinib gvhd
pemigatinib cca compani on-going trial site us eu itacitinib
gvhd topic ruxolitinib vitiligo ad data ad trial present
virtual revolution atop dermat meet april
suppli chain risk plan maintain month safeti stock api
compani believ abl respond chang demand provid on-tim suppli
drug product well least month semi-finish good inventori said raw
materi use manufactur ruxolitinib phosphat api jakafi suppli
chinese-bas compani pose inher risk current environ
financ risk forese need capit given profit commerci busi
cash hand debt/ltm ebitda
potenti valuat impact use price januari prior market shock
current consensu estim ep estim could trade
disrupt lead flat yoy earn turn price-to-earnings multipl compress
price end januari figur
scenario forward price-to-earnings multipl
commerci risk n/a yet commerci compani plan
commerci margetuximab current standard review fda breast
clinic trial risk trial site us eu asia underway margetuximab gastric
cancer us trial underway enoblituzumab scchn report impact
current studi stage follow-up manag howev compani
factor slight delay start mahogani modul led zai lab
financ risk macrogen expect need access capit compani
cash balanc project suffici fund cash usag
compani estim extend cash runway note may
priorit program partnership think rais capit current
environ may challeng ev
clinic trial risk us trial underway nsclc follow-up
manag mirati state direct impact across supplier compani
multi-sourc ds dp across multipl countri current ad supplier
specif februari compani begun enrol phase registr
arm krystal trial monotherapi nsclc compani also initi
combin trial pembrolizumab nsclc cetuximab colorect cancer
expect data updat world lung aug esmo septemb
financ risk mirati expect rais capit next year compani
cash hand complet follow-on equiti offer januari
overal see commerci stori mostli intact see lower risk eros
exist patient base expect ingrezza new patient start may impact pandemic-
relat disrupt continu
commerci risk expect potenti exacerb season volatil possibl
greater impact mitig specialti pharmaci distribut ingrezza typic impact
season trend may magnifi disrupt someth
could see come vs season typic expect ingrezza howev note
prescript fill via direct-to-pati mail specialti distribut believ
like mitig signific impact patient compliance/refil rate beyond
near-term see risk ingrezza may meet growth target estim ingrezza
area depend addit penetr previous untreat td patient new patient
start may reduc patient seek delay reduc clinic interact adher
social distanc protocol opicapon potenti launch april parkinson diseas may
clinic trial risk phase trial ingrezza huntington diseas current enrol
top-line result expect across coverag see potenti
disrupt trial enrol across geographi includ us
compani yet disclos delay on-going clinic trial
suppli chain risk none disclos unrel compani report
opicapon commerci partner bial disrupt suppli chain due incid
one contract manufactur compani coordin bial gain greater
clariti avail suppli state unlik launch drug without
certainti continu suppli expect disrupt may delay commerci
launch opicapon
financ risk immin need cash compani end
balanc sheet core busi profit limit need addit capit
regeneron effort develop treatment contribut degre
share price resili outsid develop see potenti risk eylea
dupix sale expect exist dupix patient continu receiv treatment
anticip new patient start particularli asthma reduc patient defer
non-crit physician interact potenti impact dupix abil meet consensu growth
estim anticip patient may seek postpon eylea inject possibl
lengthen dose interv hear ophthalmologist consid
inject essenti patient could irrevers lose vision other see in-offic
visit high risk older patient diabet two categori elev
risk sever complic
treatment regeneron report scientist isol hundr antibodi
mice also take antibodi patient recov
compani plan select two-thre antibodi cocktail treatment target sars-
spike protein antibodi target spike protein singl glycoprotein
viru surfac use viru bind host cell cocktail evalu
potenti prophylaxi exposur viru treatment alreadi infect patient
regeneron project human clinic trial could start earli summer
regeneron also develop kevzara anti compani believ il-
may play role over-react inflammatori respons lung patient
us phase trial led regeneron current enrol patient endpoint evalu
one month sanofi lead upcom ex-u trial await addit clariti regulatori
timelin either program success expect share price appreci sentiment-
driven upsid howev anticip meaning durabl
commerci busi beyond opportun present immedi pandem
revenu risk believ dupix at-hom self-administr mitig sever
disrupt exist patient howev expect see degre slow-down new
patient start asthma given on-going launch across coverag expect patient
reduc discretionari clinic interact given adher social distanc protocol
neg impact new patient start complianc particularli treatment unabl
self-administ see risk eylea due in-offic administr eylea
week dose interv may reduc impact patient may look lengthen
dose interv possibl minim offic visit
trial risk trial site us eu on-going fasinumab pain
fulli enrol expect clinic trial non-lif threaten indic may
disrupt due trial libtayo nsclc includ site eu
asia current enrol anticip oncolog trial less impact
pandem note multipl studi site eu asia may impact pandem
respons measur compani disclos trial disrupt date
suppli chain risk convers compani manag state
regeneron pois handl suppli disrupt note current year
drug substanc eylea reserv well ampl materi market pipelin
financi risk limit regeneron end cash forese
need rais addit capit capac rais debt need current debt/ltm
potenti valuat impact use price januari prior market shock
current consensu estim ep estim regeneron could trade
disrupt lead flat yoy earn growth turn price-to-earnings multipl
compress price end januari figur
scenario forward price-to-earnings multipl
clinic trial risk migrain studi underway unit state compani
disclos trial disrupt date still note trial current
enrol especi non-lif threaten condit approv treatment
migrain risk enrol delay home natur trial includ e-diari
track mitig risk
financ risk speak compani compani indic suffici cash
compani end cash hand project spend
think vertex rel well-posit among biotech peer believ vertex oral
self-administ treatment seriou rare diseas less like impact covid-
disrupt see risk timelin earlier portfolio mani investor
yet assign signific valu see valuat impact limit
revenu risk believ vertex cystic fibrosi portfolio rel well-insul
sever disrupt vertex therapeut disease-alt oral administ treatment
rare diseas expect patient complianc refil rate remain close normal level
expect on-going launch trikafta patient age impact given
sever natur cf
still see risk eu approval/ reimburs decis tripl combin
patient age approv symkevi eu patient may also delay
trial risk studi current enrol patient us eu site includ cf
scd us enrol underway
across coverag see potenti
disrupt trial enrol across geographi includ us compani yet
disclos anticip delay on-going clinic trial
close watch triala trial began enrol januari delay
could disappoint given high investor interest program
suppli chain risk reach comment compani state construct
suppli chain situat like one mind prepar conting
build signific safeti stock suppli chain manag disrupt addit
second sourc supplier geograph divers addit confid
uninterrupt commerci suppli expect disrupt suppli medicin
use clinic trial
financ risk immin need capit compani end cash
balanc sheet debt
potenti valuat impact use price januari prior market shock
current consensu estim ep estim regeneron could trade
disrupt lead flat yoy earn growth turn price-to-earnings multipl
compress price end januari figur
scenario forward price-to-earnings multipl
compani mention price
